Vergleichende Untersuchungen zur immunaktiven Wirkung von galaktosid-spezifischem Mistellektin; Reinsubstanz gegen standardisierten Extrakt

Journal/Book: Arzneim.-Forsch./Drug Res. 43 (2), 166-169. 1993;

Abstract: Cellular and humoral aspects of the immunomodulating activity of thegalactoside-specific lectin from mistletoe (ML-1) were investigated incancer patients suffering from mammary carcinoma and compared to theimmunoactive potency of a proprietary mistletoe extract standardized forML-1 (ML-1 stand., Eurixorregistered trade mark). Regular subcutaneousinjections of the optimal dose of ML-1 and ML-1 stand. (1 ng/kg bodyweight; twice a week; for 4 weeks) yielded statistically significantincreases of certain lymphocyte subsets (helper T-lymphocytes, naturalkiller (NK)-cells) which are generally believed to be involved inantitumor activity. Moreover, administration of either ML-1 preparationresulted in enhanced expression of interleukin (Il)-2 receptors onlymphatic cells and significantly increased serum levels of definedacute phase reactants (c-reactive protein, haptoglobin, C3 complement)as indicator of cellular and humoral activity. In vitro, exposition ofhuman lymphocytes to ML-1 and ML-1 stand, resulted in enhancedexpression of Il-2 receptors, which substantiated the capacity of bothML-1 preparations to affect immunological parameters within the hostdefense system. The effects of ML-1 and ML-1 stand. were comparable.

Keyword(s): Medical:breast-carcinoma /drug therapy

Zurück | Weiter